Item 5.07. Submission of Matters to a Vote of Security Holders.

On June 14, 2023, Homology Medicines, Inc. (the "Company") held its Annual Meeting of Stockholders. A total of 45,565,496 shares of common stock were present online or represented by proxy at the meeting, representing approximately 78.84% percent of the Company's outstanding common stock as of the April 17, 2023 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2023.

Item 1 - Election of two Class II Directors to serve until the Company's 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.



                          Votes        Votes       Broker
NOMINEE                    FOR       WITHHELD    Non-Votes
Steven Gillis, Ph.D.    32,246,621   2,619,932   10,698,943
Albert Seymour, Ph.D.   34,681,867    184,686    10,698,943

Item 2 - Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.



  Votes       Votes      Votes      Broker
   FOR       AGAINST   ABSTAINED   Non-Votes
44,765,597   108,239    691,660        0

Based on the foregoing votes, Steven Gillis, Ph.D. and Albert Seymour, Ph.D. were elected as Class II Directors and Item 2 was approved.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses